GU02-41 prostate cancer study published in Clinical Genitourinary Cancer
Congratulations to the GU02-41 team!
Citation:
Hahn NM, Yiannoutsos, C, Kirkpatrick K, Sharma J, Sweeney, CJ. Failure to suppress markers of bone turnover on first line hormonal therapy for metastatic prostate cancer is associated with shorter time to skeletal related event: Hoosier Oncology Group GU02-41. Clin Genitourin Cancer. 2013 Oct 12.
Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has initiated more than 150 trials in a variety of cancer types and supportive care, resulting in more than 300 publications. More than 4,400 patients have participated in Hoosier Cancer Research Network clinical trials.
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter